Aditya Rawat: Clopidogrel, CYP2C19 and the Role of Pharmacogenetics
Aditya Rawat, Trainee Pharmacy Assistant at City Hospital and Research Centre, Haryana, India, shared a post on LinkedIn about recent article, Yo Han Jung et al, published in JAMA, adding:
“A drug only works if your body actually turns it on.
This week in Pharmacology we started on prodrugs.
These are medicines that are inactive as swallowed and need the liver to convert them.
Clopidogrel, a widely used antiplatelet after stroke and heart attack, is a classic example. Its activation depends heavily on one enzyme, CYP2C19.
I read a 2025 JAMA Network Open trial that followed 2,910 stroke patients in South Korea, all genotyped for CYP2C19.
61 percent carried a loss of function allele.
Over six months, carriers had more cardiovascular events than non carriers (2.7 percent vs 1.6 percent).
After adjustment, non carriers had roughly 42 percent lower risk, with no difference in bleeding.
What stood out to me:
- The common variants link straight back to molecular biology. 2 disrupts splicing and 3 introduces a premature stop codon.
- The absolute difference is small and the trial wasn’t randomised, so this supports, rather than proves, genotype guided prescribing.
- A platelet function test didn’t predict outcomes, but the genotype did.
It’s a neat case where pharmacokinetics, genetics and clinical outcomes all meet in one tablet.”
Title: Cytochrome P450 2C19 Genotypes and Clopidogrel in Patients With Ischemic Stroke
Authors: Yo Han Jung, Tae-Jin Song, Jinkwon Kim, Hee-Kwon Park, Sang Won Han, Young Dae Kim, Jong-Ho Park, Jae-Kwan Cha, Hyun Young Park, Sung-Il Sohn, Sungwook Yu, Jun Hong Lee, Dong Hoon Shin, Eung-Gyu Kim, Hye Sun Lee, Kyung-Yul Lee
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series